



# EMHH 2026

24<sup>TH</sup> EUROPEAN MEETING  
ON HIV & HEPATITIS

TREATMENT  
STRATEGIES &  
ANTIVIRAL DRUG  
RESISTANCE

**BARCELONA, SPAIN** | 10-12 June 2026



## Program Book

**ve | ams**

[AcademicMedicalEducation.com](http://AcademicMedicalEducation.com)



## Abstracts

Accepted abstracts are published in the official abstract book of the **24th European Meeting on HIV & Hepatitis (EMHH) 2026**. The abstract book is available on the meeting's webpage.

## Badge Policy

Please wear your badge at all times to ensure admission to the meeting. No spare badges can be issued.

## Certificate of Attendance

The certificate of attendance will be sent by e-mail to participants that have successfully completed the program and filled in the post-meeting surveys.

## Code of Conduct

All individuals are required to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. Please report any incidents to VE and AME via [info@amededu.com](mailto:info@amededu.com) or to one of our onsite personnel. Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.

**View Code of Conduct in full:**

[academicmedicaleducation.com/  
our-commitment-diversity-and-inclusion](https://academicmedicaleducation.com/our-commitment-diversity-and-inclusion)

## Feedback Form and Post-Meeting Survey

Your feedback is very valuable to us and enables us to further improve this program. At the end of each meeting day, a survey will be sent to you via e-mail. The post-meeting survey will be sent to all registered delegates after the end of the meeting. We would like to kindly ask you to complete it.

## Networking Opportunities

Make use of the options to network during the coffee breaks, lunches, reception, and networking dinner. The reception is accessible to all registered delegates and is included in the registration fee. The **reception** takes place on **Wednesday, 10 June 2026 at 18:30 CEST**.

## Networking Dinner

The **networking dinner** takes place on **Thursday, 11 June 2026 at 19:30 CEST** at **Asador del Mar Restaurant**, Carrer de Bori i Fontestà, 45, Sarrià-Sant Gervasi, 08017 Barcelona.

The networking dinner is available to all registered delegates for an additional fee. Please contact the onsite team if you would like to purchase a ticket.

---

**Disclaimer:** This workshop aims to offer participants the opportunity to share information. Virology Education cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the conference.



## Posters

During the meeting, all accepted posters are displayed in the poster area. The poster area is always open for you.

There will also be 2 guided poster tours.

**Poster Tour 1** on **Wednesday, 10 June 2026** at **17:30 CEST**.

**Poster Tour 2** on **Thursday, 11 June 2026** at **17:45 CEST**.

## Social Media

We encourage you to post news and tweet about **#EMHH** on your social media accounts during the meeting. You can either post your own tweets or retweet a message from the official [@Academic\\_MedEdu](https://twitter.com/Academic_MedEdu).

## Venue

The **24th European Meeting on HIV & Hepatitis (EMHH) 2026** will be held at Hotel NH Collection Barcelona Costanza, Meeting Room Barcelona.



The **24th European Meeting on HIV & Hepatitis 2026, Barcelona, Spain, 10/06/2026 - 12/06/2026**, organized by **Virology Education B.V.** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of **12.5** European CME credits (ECMEC®s). Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at <https://edhub.ama-assn.org/pages/applications>.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.



## Wednesday, 10 June 2026

Central European Summer Time (CEST)

### Opening of the Meeting

- 14:00 **Opening Words**  
**Jonathan Schapiro, MD**  
 National Hemophilia Center, Sheba Medical Center, Israel
- 14:05 **Welcome to Barcelona**  
**Josep M. Llibre, MD, PhD**  
 Fundació Lluita contra la Sida; Hospital Universitari Germans Trias i Pujol, Spain

### Session 1: HIV Drug Resistance - Update 2026

*Session Chairs: Jonathan Schapiro and Josep Llibre*

- 14:15 **CROI Resistance Summary Lecture 1 - Basic Science**  
**Charlotte Charpentier, PharmD, PhD**  
 Hôpital Bichat-Claude Bernard, France
- 14:30 **CROI Resistance Summary Lecture 2 - Clinical Science**  
**Miłosz Parczewski, MD, PhD**  
 Pomeranian Medical University, Poland
- 14:45 **WHO Integrated Drug Resistance Action Framework 2026–2030**  
**Michael R. Jordan, MD, MPH, FIDSA**  
 Tufts University and Tufts Medical Center, United States

### 15:00 Discussion

### 15:45 Coffee Break

### Session 2: Epidemiology Trends - STI / HIV/ vHep

*Session Chairs: Miłosz Parczewski and David van de Vijver*

*Oral Abstract Presentations:*

- 16:15 **Diverging HIV-1 Variant Trends across the WHO European Subregions** #1  
*Karol Serwin - Poland*
- 16:25 **HIV-1 sub-subtype A6 epidemic in Italy: characteristics and phylogenetic analysis** #2  
*Alessia Lai - Italy*
- 16:35 **Two Faces of an Epidemic: Distinct Clinical and Molecular Profile of HIV-1 Infection among MSM and Heterosexual Individuals in Cyprus, 2021–2025** #3  
*Eirini Hadjioannou - Cyprus*

### Round Table: Migration as a Driver of Public Health Change in Europe

- 16:45 **Access to HIV and HBV Care for Migrants in Europe**  
**Alena Kamenshchikova, PhD**  
 Care and Public Health Research Institute (CAPHRI), Maastricht University, The Netherlands
- 17:00 **Situation in Central and Eastern Europe (migration from Ukraine)**  
**Tetiana Melnyk, MD, PhD**  
 Pierre Louis Institute of Epidemiology and Public Health, Sorbonne University, INSERM, France
- 17:00 **Situation in South Europe (migration from Africa)**  
**Nicola Coppola, MD, PhD**  
 University of Campania, Luigi Vanvitelli, Italy



|       |   |     |
|-------|---|-----|
| 17:30 | <b>Guided Poster Tour 1</b><br><i>Moderator: Francesca Ceccherini-Silberstein</i>   |     |
|       | <b>Resistance to the HIV-1 Capsid Inhibitor Lenacapavir</b><br><i>Christian Callebaut - United States</i>   | #27 |
|       | <b>Accurate Detection of HIV Drug Resistance Mutations Using Oxford Nanopore Sequencing: A Comparative Study with Illumina NGS</b><br><i>Nadine Lübke - Germany</i>                                       | #44 |
|       | <b>Comparative Evaluation of the New Abbott HIV Combonext Serological Assay and the Roche Elecsys HIV Duo Test : Analytical and Clinical Performance</b><br><i>Erwan Lanio - France</i>                   | #45 |
|       | <b>No Cross-Resistance and Effective in Vitro Coverage of HIV-1 with Primary Reverse Transcriptase Resistance by a Combination of Islatravir and Lenacapavir</b><br><i>Elena Bekerman - United States</i> | #74 |
|       | <b>Characterization of HIV-1 Non Canonical Mutations in Cameroonians who failed a DTG-based regimen</b><br><i>Naomi-karell Etame - Cameroon</i>   | #76 |

18:30 **Networking Reception**

19:30 **End of Day 1**



## Thursday, 11 June 2026

Central European Summer Time (CEST)

### Session 3: Biomarkers for Viral Infections

Session Chairs: Francesca Ceccherini-Silberstein and Martin Obermeier

08:30 **HIV DNA as a Biomarker - Ready for the Clinic?**

**Maria Santoro, PhD**

University of Rome "Tor Vergata", Italy

08:45 **Role of Novel Biomarkers for HBV-HDV**

**Valentina Svicher, PhD**

University of Rome "Tor Vergata", Italy

*Oral Abstract Presentations:*

09:00 **HBsAg isoforms vary according to HDV subgenotypes and their levels distinguish the different disease stages of chronic HDV infection** #4

Stefano D'Anna - Italy

09:10 **Integrating Neurocognitive Assessment and Plasma Proteomics to Identify Biomarkers of Neurocognitive Impairment in Aging People With HIV** #5

Iris Teubel - Spain

09:20 **Discussion**

09:30 **Session 4: What's in the HIV Pipeline? Presentations on Future Viral Therapeutics**

(Full Program at Page 11)

10:30 **Coffee Break and Odd-Numbered Posters Viewing**

### Session 5: Low-Level Viremia - What Is It and What Do We Do with It?

Session Chairs: Dimitrios Paraskevis and Anna Maria Geretti

11:00 **Detecting it - How Low can we go - Viral Load / Resistance**

**Anne-Geneviève Marcelin, MD**

Pitié-Salpêtrière Hospital, Sorbonne Université, France

11:15 **What to do - Clinical Perspective**

**Huldrych F. Günthard, MD**

University Hospital Zurich and Institute of Medical Virology, University of Zurich, Switzerland

11:30 **Impact of LLV on Viral Evolution**

**Roger Paredes, MD, PhD**

Hospital Germans Trias & IrsiCaixa AIDS Research Institute, Spain

11:45 **Discussion**

12:15 **Industry-supported Symposium**

(Symposium Program at page 11)

13:00 **Lunch Break**

14:00 **Industry-supported Symposium**

(Symposium Program at page 11)



## Session 6: Abstract-Driven Session

Session Chairs: Rolf Kaiser and Charlotte Charpentier

Oral Abstract Presentations:

- |       |   |     |
|-------|---|-----|
| 14:45 | <p><b>Changes in HIV-1 Reservoirs in Virologically Suppressed People with HIV-1 One Year After Receiving Lenacapavir and the Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab</b></p> <p>Laurie VanderVeen - United States</p>       | #6  |
| 14:55 | <p><b>Multidisciplinary assessment of the HIV-1 reservoir after switching from triple to dual antiretroviral therapy in virologically suppressed individuals, a prospective observational pilot study.</b></p> <p>Niccolò Bartolini - Italy</p> | #7  |
| 15:05 | <p><b>Automated Real-Time Molecular Surveillance Platform Reveals HIV-1 Drug Resistance Dynamics and Transmission Cluster Origins among MSM across Europe</b></p> <p>Beatriz Valadas - Portugal</p>   | #8  |
| 15:15 | <p><b>Relevance and Value of Sequencing the 5' Leader Region of HIV-1 in Plasma in Clinical Practice.</b></p> <p>Anne-Geneviève Marcelin - France</p>   | #9  |
| 15:25 | <p><b>Added Value of RNA-Based Whole Genome Sequencing in Viremic People with 4-Class Drug-Resistant HIV: Insights from the PRESTIGIO Registry</b></p> <p>Tommaso Clemente - Italy</p>  | #10 |
| 15:35 | <p><b>Evaluation of HIV-1 Integrase Resistance Patterns and Associated Clinical Factors in individuals who failed dolutegravir containing regimens in Cameroon</b></p> <p>Collins Ambe Chenwi - Italy</p>                                       | #11 |

15:45 **Discussion**

16:00 **Coffee Break and Even-Numbered Posters Viewing**

## Session 7: Clinical Considerations Using Long-Acting Antivirals

Session Chairs: Anne-Geneviève Marcelin and Gary Rubin

- |       |  |
|-------|--|
| 16:30 | <p><b>bNAbs Resistance - Detection &amp; Implication</b></p> <p><b>Robert Shafer, MD</b></p> <p>Stanford University, United States</p>   |
| 16:45 | <p><b>Use of LA - ART in Challenging Patients</b></p> <p><b>Sanjay Bhagani, BSc, FRCP</b></p> <p>Royal Free London NHS Foundation Trust, United Kingdom</p>  |
| 17:00 | <p><b>TDM for CAB/RPV in Failing Patients - The Swiss Approach</b></p> <p><b>Catia Marzolini, PharmD, PhD</b></p> <p>University Hospital of Basel, University Hospital of Lausanne, Switzerland; University of Liverpool, United Kingdom</p> |
| 17:15 | <p><b>TDM for CAB/RPV in Failing Patients - The Spanish Approach</b></p> <p><b>José Moltó, MD, PhD</b></p> <p>Hospital Universitari Germans Trias i Pujol, Spain</p>   |

17:30 **Discussion**



|       |   |     |
|-------|---|-----|
| 17:45 | <b>Guided Poster Tour 2</b><br><i>Moderator: Federico García</i>  |     |
|       | <b>Extensive HDV genetic diversity and high rates of active infection in Cameroon revealed by molecular diagnostics and Whole-Genome Sequencing</b><br><i>Lorenzo Piermatteo - Italy</i>                            | #18 |
|       | <b>HIV-1 Whole Genome Sequencing for Comprehensive Genotype Resistance Testing</b><br><i>Federica Stefanelli - Italy</i>  | #48 |
|       | <b>The Enhanced Resistance Profile of Third-Generation INSTI VH4524184 (VH-184) vs Bictegravir</b><br><i>Jon Collins - United States</i>  | #55 |
|       | <b>Europe is still characterized by a relevant burden of HDV infection and double reflex testing can be valuable to increase HDV diagnosis at an earlier stage of liver disease</b><br><i>Ilaria Grossi - Italy</i> | #75 |
|       | <b>Optimising HIV-1 5' Leader Region Sequencing to Detect Non-Suppressible Viraemia</b><br><i>Federico García - Spain</i>   | #78 |

|       |  |  |
|-------|--|--|
| 18:45 | <b>End of Day 2</b>  |  |
| 19:30 | <b>Networking Dinner</b> <i>(for faculty and attendees who registered separately for the Dinner)</i> |  |



**Friday, 12 June 2026**

Central European Summer Time (CEST)

## Session 8: Management of Viral Hepatitis

Session Chairs: *Federico García and Pavel Khaykin*

09:00 **Hepatitis Treatment - Overview on the Different Modes of Actions**

**Stanislas Pol, MD, PhD**

Cabinet des Augustines, Hepatology, France

09:15 **Hepatitis Pipeline - What is Coming**

**Sabela Lens, MD, PhD**

Liver Unit, Hospital Clinic / FCRB-IDIBAPS / University of Barcelona / CIBERehd, Spain

*Oral Abstract Presentations:*

09:30 **Hepatitis Delta in Spain: Nationwide Prevalence and Comprehensive Clinical and Virological Characterization** #12

*Ana Alberola Romano - Spain*

09:40 **Hepatitis Delta antigen and ribozyme genetic variability is associated with altered virological and biochemical markers and provides basis for the identification of novel therapeutic targets** #13

*Alessia Magnapera - Italy*

09:50 **Acute Hepatitis B Cluster Among MSM: Possible Concerns on New ART and PrEP Strategies** #14

*Rémi Rouget - France*

10:00 **Discussion**

10:20 **Coffee Break**

## Session 9: Controversies in Clinical Virology - The Impact of Polymorphisms

Session Chairs: *Francesca Ceccherini-Silberstein and Josep Llibre*

10:50 **Detecting APOBEC Driven Variation - How Do You Determine/Detect APOBEC Variation**

**Martin Obermeier, MD**

German Heart Centre Berlin (DHZB) / Medical Centre for Infectious Diseases in Berlin MVZ mib AG, Germany

11:10 **APOBEC-Driven Variation in HIV: Does It Change Clinical Decisions?**

**Anna Maria Geretti, MD, PhD, FRCPath**

University of Rome, Italy / Royal Free London NHS Foundation Trust, United Kingdom

*Oral Abstract Presentations:*

11:30 **Characterization of Intrinsic Susceptibility to APOBEC3-Mediated G-To-a Transitions across the HIV-1 Mutational Landscape: Implications for Capsid and Enzymatic Targets** #15

*Hossein Eizadi-Moghadam - Italy*

11:40 **Contribution of Plasma Next-Generation Sequencing to Resistance Assessment at Virological Failure Compared with Cumulative Historical Genotypes: Data from the ARCA Cohort and the Italian NGS Network** #16

*Daniele Armenia - Italy*

11:50 **Discussion**

12:20 **Lunch Break**



## Session 10: HIV Drug Resistance - Complex Interpretation

Session Chairs: *Jonathan Schapiro and Maria Santoro*

- 13:20 **Regimen Potency - Regimen-Specific Resistance Risks**  
**Josep M. Llibre, MD, PhD**  
Fundació Lluita contra la Sida; Hospital Universitari Germans Trias i Pujol, Spain
- 13:40 **Second Generation INSTI resistance - Noncanonical Resistance Mutations**  
**Francesca Ceccherini-Silberstein, PhD**  
University of Rome "Tor Vergata", Italy
- 14:20 **Interpretation of "Historical" Genotypes - Plasma & DNA**  
**Federico Garcia, PharmD, PhD**  
University Hospital San Cecilio, Spain

14:40 **Discussion**

## Closure of the Meeting

- 15:00 **Closing Remarks**  
**Jonathan Schapiro, MD**  
National Hemophilia Center, Sheba Medical Center, Israel  
**Josep M. Llibre, MD, PhD**  
Fundació Lluita contra la Sida; Hospital Universitari Germans Trias i Pujol, Spain

15:10 **End of the Meeting**



**Thursday, 11 June 2026**

Central European Summer Time (CEST)

## Session 4: What's in the HIV Pipeline? Presentations on Future Viral Therapeutics

Session Chair: *Jonathan Schapiro*

09:30 **Gilead Sciences**

**Martin Rhee, MD**

Gilead Sciences, United States

09:45 **ViiV Healthcare**

**Jean van Wyk, MD, ChB**

ViiV Healthcare, United Kingdom

10:00 **MSD**

**Rafael Eduardo Campo, MD**

MSD, United States

10:15 **Discussion**

10:30 **Coffee Break and Odd-Numbered Posters Viewing**

## *ViiV Healthcare Symposium - Can LLV be managed without compromising patient preferences?*

Moderator: *Federico Garcia*

12:15 **Welcome and introduction**

**Federico Garcia, PharmD, PhD**

University Hospital San Cecilio, Granada, Spain

12:18 **Part 1: Clinical case discussion: What drives LLV in people receiving HIV treatment?**

**What mechanisms could be driving LLV in a person who is receiving ART?**

**Jonathan Schapiro, MD**

Sheba Medical Center, Tel Aviv, Israel

**What are the possible benefits and considerations for the use of LA treatment options in people with LLV?**

**Miłosz Parczewski, MD, PhD**

Pomeranian Medical University, Szczecin, Poland

12:33 **Part 2: Clinical case discussion: How could we manage LLV in people receiving HIV treatment?**

**What are the factors to consider when managing LLV in people receiving HIV treatment?**

**Miłosz Parczewski, MD, PhD**

Pomeranian Medical University, Szczecin, Poland

**What are the specific factors to consider for people receiving LA treatment options and when is TDM necessary?**

**Jonathan Schapiro, MD**

Sheba Medical Center, Tel Aviv, Israel

12:48 **Panel Discussion and Q&A: Balancing patient preferences and evidence-based LLV management**

**Federico Garcia, PharmD, PhD**

University Hospital San Cecilio, Granada, Spain

**Jonathan Schapiro, MD**

Sheba Medical Center, Tel Aviv, Israel

**Miłosz Parczewski, MD, PhD**

Pomeranian Medical University, Szczecin, Poland

12:58 **Key lessons for clinicians managing LLV**

**Federico Garcia, PharmD, PhD**

University Hospital San Cecilio, Granada, Spain



---

**MSD Symposium - From triple therapy to two drug options: Where a modern NNRTI fits today and tomorrow**

Moderator: Jonathan Schapiro

---

14:00 **Welcome and introduction**

**Jonathan Schapiro, MD**

National Hemophilia Center Sheba Medical Center Ramat Gan, Israel

14:05 **When viral control isn't enough: Addressing ART side effects**

**Sebastian Noe, MD, PhD**

MVZ Care, Munich, Germany / Technical University of Munich School of Medicine, Munich, Germany

14:15 **When standard options don't fit: Navigating complexity in older people**

**Roger Paredes, MD, PhD**

Hospital Universitari Germans, Trias i Pujol, Badalona, Spain

14:25 **When "preferred" isn't chosen: The gap between guidelines and practice**

**Anna Maria Geretti, MD, PhD, FRCPATH**

Royal Free London NHS Trust London, United Kingdom / University of Rome Tor Vergata Rome, Italy

---

14:35 **Panel discussion and Q&A**

Moderator:

**Jonathan Schapiro, MD**

National Hemophilia Center Sheba Medical Center Ramat Gan, Israel

---

14:45 **Summary and close**

**Jonathan Schapiro, MD**

National Hemophilia Center Sheba Medical Center Ramat Gan, Israel

---



## CORPORATE SUPPORT

### GOLD LEVEL SPONSORS

---



Support provided by ViiV Healthcare

### SILVER LEVEL SPONSOR

---



Supported by Gilead who provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.

### ENDORSERS

---



